Pharmacoeconomic Analysis of Chemotherapy Regimens in Breast Cancer Management; An Oncology Pharmacoeconomical Approach
Baharul Islam Haidary1, Rajesh Venkataraman2★, Irshad Pasha3★ Corresponding author
- 1Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B. G. Nagara, Mandya, Karnataka, INDIA.
- 2Department of Pharmacy Practice, Parul University, Vadodara, Gujarat, INDIA.
- 3Department of Clinical Pharmacy, Adichunchanagiri Hospital, B G Nagara, Mandya, Karnataka, INDIA.
CORRESPONDENCE
Rajesh Venkataraman
Department of Pharmacy Practice, Parul University, Vadodara, Gujarat, INDIA.
Received: 02-05-2025; Revised: 21-07-2025; Accepted: 12-09-2025.
Volume 17, Issue 4 · pp. 970–979 · PUBLISHED · DOI: 10.5530/jyp.20250162
ABSTRACT
Background:Pharmacoeconomic evaluation of breast cancer drugs is essential due to their high treatment costs. Comparing therapeutic options and associated expenses supports better decision-making and helps optimize resource utilization. Increased clinician awareness of pharmacoeconomic principles can enhance patient outcomes while reducing overall treatment costs. This study aims to evaluate the pharmacoeconomic aspects of different therapeutic regimens used in the management of breast cancer. Materials and Methods:A 12-month prospective observational and economic study was conducted at Bharath Hospital and Institute of Oncology (BHIO), Mysore, Karnataka. A total of 204 breast cancer patients receiving chemotherapy and meeting study criteria were included. Data from patient records and questionnaires were analyzed to evaluate the Pharmacoeconomics of chemotherapy regimens. Results:A total of 204 patients (mean age 52±8.9 years) were included. Adriamycin, Cyclophosphamide, and Paclitaxel (Regimen 1) were most prescribed (34.31%). Average management cost was ₹2,93,114.67; direct and indirect costs were ₹6,16,591.7 and ₹8,374.11, respectively. Adjuvant treatment averaged ₹3,25,807, and neoadjuvant ₹15,88,77.5 Regimen 1 showed most cost-effective, with 28.57% excellent and 68.57% moderate quality of life. Costs were significantly higher in adjuvant settings. Conclusion:Breast cancer treatment places a considerable economic strain on both patients and healthcare systems. Enhancing health insurance and resource-sharing strategies is crucial to reduce this burden. Additional support services may also be needed to ease patient expenses. Conducting pharmacoeconomic assessments of available treatment options can assist policymakers in allocating healthcare resources more efficiently for cancer management.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Haidary, B. I., Venkataraman, R., & Pasha, I. (). Pharmacoeconomic Analysis of Chemotherapy Regimens in Breast Cancer Management; An Oncology Pharmacoeconomical Approach. Journal of Young Pharmacists, 17(4), 970–979. https://doi.org/10.5530/jyp.20250162